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Introduction
Pneumocystis pneumonia (PCP) is an opportunistic
infection affecting patients with congenital or acquired
immunodeficiency. In rheumatology, PCP is occasionally
seen as a life threatening event complicating the course
and treatment of a variety of diseases, especially vasculi-
tides and systemic connective tissue disorders.
Objectives
To show possible complications of the immunosuppres-
sive treatment of systemic onset juvenile idiopathic
arthritis (soJIA) and also demonstrate possible adverse
effects and alternatives of antimicrobial treatment of
PCP.
Methods
A case report of a girl with soJIA and Pneumocystis
infection.
Results
A 6-year-old girl with soJIA treated with high doses of
corticosteroids and cyclosporine for 6 months was sent to
the Paediatric Rheumatology Centre at the Paediatric
Department of the University Hospital Brno, Czech
Republic. For lasting systemic symptoms (fever, rash, high
inflammatory markers) and active knee arthritis the ther-
apy with tocilizumab was initiated after discontinuation of
cyclosporine. There was a history of repeated antibiotic
and antifungal therapy for upper respiratory infections
before starting the biological treatment. At the time of the
first tocilizumab infusion, chest radiograph was negative,
white blood cell count including neutrophils and lympho-
cytes was normal, the total IgG level was only slightly
reduced. After the second dose of tocilizumab the corti-
costeroids could be tapered, but the girl presented with
nonproductive cough and dyspnea. On the basis of typical
symptoms, HRCT findings and highly positive PCR for
Pneumocystis jiroveci in bronchoalveolar lavage the
diagnosis of PCP was established and tocilizumab was dis-
continued. The first line PCP treatment with i.v. trimetho-
prim-sulfamethoxazole (TMP-SMX) for 17 days was
successful, but it was complicated by agranulocytosis
requiring application of colony stimulating factors and
antibiotic treatment for febrile neutropenia. Granulocyte
count was promptly normalized but simultaneously signif-
icant hypogammaglobulinemia occurred with the absence
of CD20+ and significant decrease of CD19+ lymphocytes
in peripheral blood, while the counts of T lymphocytes
including CD4+ were normal. Monthly substitution by
intravenous immunoglobulins (IVIGs) was required for six
months until sustained normalization of plasma immuno-
globulins was achieved. Intravenous pentamidine every
4 weeks has been used in the secondary PCP prophylaxis.
The dose of corticosteroids could be significantly
decreased because of inactivity of soJIA for a long period
of expressed secondary immunodeficiency. However, eight
months after setting the diagnosis of PCP the soJIA flared,
possibly in connection with the restitution of the immune
response. The therapy with anakinra was started with
good response enabling corticosteroid withdrawal within 5
months. Now, the girl is without any difficulties, there are
no clinical or laboratory signs of inflammation, her serum
immunoglobulin levels are normal as well as the number
of T-lymphocytes, even the B-lymphocyte count is almost
normal. Secondary PCP prophylaxis still continues.
Conclusion
Pneumocystis pneumonia in rheumatology should be
considered particularly in patients with secondary
immunodeficiency connected with aggressive and com-
bined immunosuppressive therapy. However, no specific
guidelines have been established for primary PCP pro-
phylaxis in patients without HIV infection. PCP treat-
ment with high doses of TMP-SMX may be associated
with significant side effects such as agranulocytosis,
which requires the use of second line drugs, for example
pentamidine. Criteria for discontinuing the secondary
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PCP prophylaxis have also not been clearly defined and
an individual approach should be used.
Disclosure of interest
None declared.
Published: 17 September 2014
doi:10.1186/1546-0096-12-S1-P225
Cite this article as: Schüller et al.: Pneumocystis pneumonia in a child
with sojia. Pediatric Rheumatology 2014 12(Suppl 1):P225.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schüller et al. Pediatric Rheumatology 2014, 12(Suppl 1):P225
http://www.ped-rheum.com/content/12/S1/P225
Page 2 of 2
